Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment.

Abstract:

OBJECTIVE:This study's objective was to quantify the impact (utility) of common complications of early cervical cancer treatment on quality of life (QOL). Utilities assigned by survivors were compared to those assigned by providers. METHODS:30 survivors of early cervical cancer identified from our Tumor Registry and 10 gynecologic oncology providers were interviewed. Participants evaluated complications (health states) using the standard gamble (SG) and visual analogue scale (VAS). Each participant was randomly assigned to rate 5 of 13 health states. Mixed-effects linear models were used to generate confidence intervals for utility means, and evaluate the effect of group (survivors versus providers). Higher utilities indicate the health state is closer to perfect health. RESULTS:Survivors and providers mean ages were similar (44 and 40). Mean time from diagnosis was 6.7 years. 28 of 30 survivors had no evidence of disease. 56% of survivors had complications. Using SG, providers consistently assigned utilities 7% higher than survivors (p=0.035) for all health states except "ileostomy", which survivors rated higher than providers. Survivors assigned the lowest utility to small bowel obstruction (SBO) (fixable without an ostomy) and ureteral obstruction (UO). Survivors rated SBO 16% and UO 21% lower than providers. Personal history of complications or higher stage did not have a consistent effect on QOL adjustments. DISCUSSION:Providers assign higher utilities than survivors to health states. Providers and survivors diverge on which complications impact QOL the most. Data on patient preferences should be considered when weighing treatment options with similar survival but different associated complications.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Einstein MH,Rash JK,Chappell RJ,Swietlik JM,Hollenberg JP,Connor JP

doi

10.1016/j.ygyno.2011.10.033

subject

Has Abstract

pub_date

2012-04-01 00:00:00

pages

163-7

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(11)00875-4

journal_volume

125

pub_type

杂志文章
  • Advanced cytoreductive surgery: Asia Pacific perspective.

    abstract::The thoroughness of cytoreductive surgery is the largest contributor to survival for patients with advanced ovarian and primary peritoneal carcinoma. For many years the surgery undertaken by Gynaecologic Oncologists has been tailored to match their surgical training. Future surgical training of Gynaecologic Oncologist...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.11.007

    authors: Crandon AJ,Obermair A

    更新日期:2009-08-01 00:00:00

  • Pathological characteristics of cervical adenocarcinoma in a multi-center US-based study.

    abstract:OBJECTIVE:Difficulties in detecting cervical adenocarcinoma early are well known. We report a detailed pathology review of cervical adenocarcinoma subtypes, comparing growth patterns and appearance of non-neoplastic epithelium to inform possible clues for disease progression and early detection. METHODS:This analysis ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2006.03.049

    authors: Wang SS,Sherman ME,Silverberg SG,Carreon JD,Lacey JV Jr,Zaino R,Kurman RJ,Hildesheim A

    更新日期:2006-11-01 00:00:00

  • Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.

    abstract:OBJECTIVE:Only a small number of comprehensively characterized immortalized ovarian cancer cell lines are available for laboratory studies on ovarian cancer. We describe a new ovarian cancer cell line that arose from primary culture of a stage IC, grade III ovarian carcinoma, designated CSOC 882. METHODS:We characteri...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.07.023

    authors: Scoles DR,Pavelka J,Cass I,Tran H,Baldwin RL,Armstrong K,Karlan BY

    更新日期:2007-01-01 00:00:00

  • Psychological adjustment to familial-genetic risk assessment for ovarian cancer: predictors of nonadherence to surveillance recommendations.

    abstract:OBJECTIVE:To evaluate whether self-report measures of psychological distress and perceived risk were associated with nonadherence to recommended ovarian cancer surveillance. METHODS:Eighty-three patients attending the Familial Ovarian Cancer Clinic (FOCC) at Princess Margaret Hospital were assessed psychosocially prio...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2001.6461

    authors: Ritvo P,Irvine J,Robinson G,Brown L,Murphy KJ,Matthew A,Rosen B

    更新日期:2002-01-01 00:00:00

  • Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

    abstract:OBJECTIVES:While most women with ovarian cancer will achieve complete remission after treatment, the majority will relapse within two years, highlighting the need for novel therapies. Cancer stem cells (CSC) have been identified in ovarian cancer and most other carcinomas as a small population of cells that can self-re...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.05.027

    authors: Skubitz AP,Taras EP,Boylan KL,Waldron NN,Oh S,Panoskaltsis-Mortari A,Vallera DA

    更新日期:2013-09-01 00:00:00

  • Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.

    abstract::The purpose of this study was to evaluate the serum tumor markers CYFRA 21-1 and squamous-cell carcinoma antigen (SCC) in the follow-up of squamous-cell cervical cancer patients. One hundred-ninety-three serum samples, which were collected pretherapeutically and during follow-up of 30 patients suffering from squamous-...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1995.1071

    authors: Kainz C,Sliutz G,Mustafa G,Bieglmayr C,Koelbl H,Reinthaller A,Gitsch G

    更新日期:1995-03-01 00:00:00

  • Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

    abstract:PURPOSE:To analyze quality of life (QOL) in a randomized, placebo-controlled phase III trial concluding that the addition of concurrent and maintenance bevacizumab (Arm 3) to carboplatin and paclitaxel prolongs progression-free survival in front-line treatment of advanced ovarian cancer compared to chemotherapy alone (...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.ygyno.2012.11.038

    authors: Monk BJ,Huang HQ,Burger RA,Mannel RS,Homesley HD,Fowler J,Greer BE,Boente M,Liang SX,Wenzel L

    更新日期:2013-03-01 00:00:00

  • Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?

    abstract::Objective. Thegoal of this study was to determine the influence of LVSI (lymphvascular space involvement) on the risk of lymph node metastases from endometrial cancer.Methods. All patients with surgically staged endometrial cancer from 1998 to 2000 were identified from divisional databases. The influence of LVSI on th...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2002.6825

    authors: Cohn DE,Horowitz NS,Mutch DG,Kim SM,Manolitsas T,Fowler JM

    更新日期:2002-12-01 00:00:00

  • C-erbB-2-oncogene expression in breast carcinoma: analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters.

    abstract::The c-erbB-2 mRNA was detected by the S1 nuclease protection assay and Northern blotting in breast cancer tissues. In contrast to the Northern blot analysis which has been used in all recent publications concerning c-erbB-2 expression on the level of RNA, the S1-nuclease protection assay has distinct advantages with r...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90111-u

    authors: Tanner B,Friedberg T,Mitze M,Beck T,Oesch F,Knapstein PG

    更新日期:1992-11-01 00:00:00

  • Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975-2009.

    abstract:BACKGROUND:Although overall cervical cancer incidence rates have decreased in both black and white women in the U.S. since the mid 1950s due to widespread screening, rates continue to be higher among blacks than among whites. However, whether this pattern differs by age is unknown. METHODS:Cervical cancer cases (1975-...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.08.021

    authors: Simard EP,Naishadham D,Saslow D,Jemal A

    更新日期:2012-12-01 00:00:00

  • Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.

    abstract:OBJECTIVE:To compare the frequencies of somatic homologous recombination (HR) gene mutations identified in next-generation sequencing (NGS) genomic profiling of uterine serous carcinomas (USCs) and high-grade serous ovarian carcinomas (HGSOCs). METHODS:Data for this analysis was obtained from AACR Project GENIE, a mul...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.08.012

    authors: Wallbillich JJ,Morris RT,Ali-Fehmi R

    更新日期:2020-11-01 00:00:00

  • Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial.

    abstract:OBJECTIVE:Minority and low-income cancer patients are underrepresented in clinical trials, contributing to diminished access to state-of-the-art care and disparities in cancer outcomes including survivorship issues. In cervical cancer, there is a disproportionate disease burden among minority and underserved women and ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.ygyno.2011.02.007

    authors: Osann K,Wenzel L,Dogan A,Hsieh S,Chase DM,Sappington S,Monk BJ,Nelson EL

    更新日期:2011-06-01 00:00:00

  • Transcript expression in endometrial cancers from Black and White patients.

    abstract:OBJECTIVE:Previous studies suggest that differences in molecular features of endometrial cancers between racial groups may contribute to the poorer survival in Blacks. The objective of this investigation was to determine whether gene expression among endometrial cancers is different between Blacks and Whites. METHODS:...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.04.017

    authors: Maxwell GL,Allard J,Gadisetti CV,Litzi T,Casablanca Y,Chandran U,Darcy KM,Levine DA,Berchuck A,Hamilton CA,Conrads TP,Risinger JI

    更新日期:2013-07-01 00:00:00

  • Immunohistochemical detection of somatostatin receptors in human ovarian tumors.

    abstract:OBJECTIVE:It is well established that many human tumors can express somatostatin receptors. This is the molecular basis for the application of long-acting somatostatin analogues for therapeutic and diagnostic purposes. However, there are discrepancies in earlier studies regarding the prevalence of somatostatin receptor...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2001.6468

    authors: Schulz S,Schmitt J,Quednow C,Roessner A,Weise W

    更新日期:2002-02-01 00:00:00

  • The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter?

    abstract:BACKGROUND:Survivorship and quality of life issues are becoming increasingly relevant in endometrial cancer as a result of the marked increase in incidence of the disease combined with excellent and improving long term survival. OBJECTIVE:The purpose of this study was to evaluate the effect of obesity on quality of li...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.11.018

    authors: Smits A,Lopes A,Das N,Bekkers R,Galaal K

    更新日期:2014-01-01 00:00:00

  • Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study.

    abstract::Between August 1990 and January 1992, 184 patients with squamous cell carcinoma of the cervix, FIGO stage IIB-IVA, were randomized to receive either two cycles of bleomycin, ifosfamide-mesna, and cis-platinum (BIP) chemotherapy (CT) followed by radiotherapy (RT) ("CT-RT group," n = 94) or RT alone (RT group, n = 90). ...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1006/gyno.1994.1215

    authors: Kumar L,Kaushal R,Nandy M,Biswal BM,Kumar S,Kriplani A,Singh R,Rath GK,Kochupillai V

    更新日期:1994-09-01 00:00:00

  • Vulvar reconstruction using a mons pubis pedicle flap.

    abstract::The treatment of early vulvar carcinoma has moved toward less radical surgery with reconstruction. This report describes our preliminary experience with a mons pubis flap that is simple and appears safe, reliable, and gives excellent cosmetic and functional results following radical hemivulvectomy. Four patients have ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1994.1240

    authors: Potkul RK,Barnes WA,Barter JF,Delgado G,Spear SL

    更新日期:1994-10-01 00:00:00

  • Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.

    abstract::Mullerian Inhibiting Substance (MIS), a fetal testicular product that causes regression of the Mullerian duct in the male mammalian embryo, was evaluated for its antitumor effect on the premise that a substance active against this genital precursor in the fetus might also be active against tumors derived from these ti...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(85)90019-8

    authors: Fuller AF Jr,Krane IM,Budzik GP,Donahoe PK

    更新日期:1985-10-01 00:00:00

  • Advanced cervical carcinoma presenting with toxic shock syndrome.

    abstract::Toxic shock syndrome is a multisystem disease which presents with a high fever, rash, gastrointestinal symptoms, and hypotension. A 58-year-old woman presented to the emergency room with these symptoms, hypotension and tachycardia. Because of vaginal spotting a pelvic examination was performed which demonstrated vulvo...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1994.1043

    authors: Rose PG,Wilson G

    更新日期:1994-02-01 00:00:00

  • Tamoxifen-induced increase in cytosol progestin receptor levels in a case of metastatic endometrial cancer.

    abstract::A patient with endometrial carcinoma metastatic to the groin has had serial cytosol estrogen (ERc) and progestin (PRc) receptor determinations during hormonal therapy. The primary lesion was well differentiated and a left iliac node metastasis had high ERc and borderline PRc levels. PRc levels increased substantially ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(83)90007-0

    authors: Schwartz PE,MacLusky N,Naftolin F,Eisenfeld A

    更新日期:1983-08-01 00:00:00

  • Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?

    abstract:BACKGROUND:Population-based studies of women with epithelial ovarian cancer suggest that black women have worse survival compared to white women. The primary objective of this study was to determine if, at a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center (CCC) serving a diverse racial and socioe...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.10.035

    authors: Dilley S,Erickson BK,Phillips CE,Kennemer CR,Zhang B,Matin T,Martin JY,Shah MM,Michael Straughn J Jr,Leath CA 3rd

    更新日期:2018-04-01 00:00:00

  • Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.

    abstract:OBJECTIVE:This study investigated the relationship between 13 proteins involved in DNA damage and the outcomes of patients with recurrent ovarian cancer (ROC). PATIENTS AND METHODS:Immunohistochemistry staining was performed in 114 diagnostic samples from patients with serous ROC who participated in the OVA-301 study,...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.10.032

    authors: Monk BJ,Kaye SB,Poveda A,Herzog TJ,Aracil M,Nieto A,Badri N,Parekh TV,Tanović A,Galmarini CM

    更新日期:2014-01-01 00:00:00

  • SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells.

    abstract:OBJECTIVE:Serous borderline ovarian tumors (SBOT) are slow growing, noninvasive ovarian epithelial neoplasms, which tend to recur as low-grade invasive carcinomas (LGC) with a much worse prognosis. We investigated the molecular basis of this progression. METHODS:We established cultures of three SBOTs and one LGC from ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.06.021

    authors: Woo MM,Salamanca CM,Symowicz J,Stack MS,Miller DM,Leung PC,Gilks CB,Auersperg N

    更新日期:2008-10-01 00:00:00

  • Relationship between removal of circumflex iliac nodes distal to the external iliac nodes and postoperative lower-extremity lymphedema in uterine cervical cancer.

    abstract:OBJECTIVE:This study aimed to determine if there is a causal relationship between removal of the circumflex iliac nodes distal to the external iliac nodes (CINDEIN) and postoperative lower-extremity lymphedema (POLEL) after systematic lymphadenectomy in patients with cervical cancer. METHODS:A retrospective chart revi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2015.09.007

    authors: Yamazaki H,Todo Y,Takeshita S,Ohba Y,Sudo S,Minobe S,Okamoto K,Yamashiro K,Kato H

    更新日期:2015-11-01 00:00:00

  • A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.

    abstract:OBJECTIVE:The aim of this study was to determine the efficacy of cisplatin, ifosfamide, and mesna in uterine malignant mixed müllerian tumor (MMMT) and to evaluate the expression of clinically relevant molecular markers. METHODS:Women with advanced or recurrent MMMT were treated every 28 days with cisplatin (75 mg/m(2...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0090-8258(03)00332-9

    authors: Ramondetta LM,Burke TW,Jhingran A,Schmandt R,Bevers MW,Wolf JK,Levenback CF,Broaddus R

    更新日期:2003-09-01 00:00:00

  • Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection.

    abstract::Women with histopathologically confirmed cervical intraepithelial neoplasia (CIN) were followed at 3-month intervals in a randomized double-blinded trial to evaluate the efficacy of beta-carotene to cause regression of CIN. Questionnaire data, plasma levels of micronutrients, and a cervicovaginal lavage for human papi...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1006/gyno.1997.4697

    authors: Romney SL,Ho GY,Palan PR,Basu J,Kadish AS,Klein S,Mikhail M,Hagan RJ,Chang CJ,Burk RD

    更新日期:1997-06-01 00:00:00

  • p16INK4A in routine practice as a marker of cervical epithelial neoplasia.

    abstract:OBJECTIVE:The aim of this study was to validate the role of p16(INK4a) immunocytochemistry as a marker of cervical epithelial neoplasia in cytology and biopsy samples. METHODS:During the period of 4 years a total of 501 immunocytochemistry stains in cytology and biopsy samples were performed. The cytology smears were ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.06.020

    authors: Kurshumliu F,Thorns C,Gashi-Luci L

    更新日期:2009-10-01 00:00:00

  • "Microinvasive" adenocarcinoma of the cervix implanting in an episiotomy scar.

    abstract::Episiotomy scar tumor implantation arising from a cervical carcinoma is rare. This report details a patient who developed an episiotomy implant from a "microinvasive" adenocarcinoma of the cervix 5 months following vaginal delivery. The implant behaved as a primary focus for metastases to the inguinal lymph nodes. Des...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1995.0025

    authors: Van den Broek NR,Lopes AD,Ansink A,Monaghan JM

    更新日期:1995-11-01 00:00:00

  • Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.

    abstract:PURPOSE:To examine the relative efficacy of cisplatin-based intraperitoneal (IP) therapy versus carboplatin-based IP therapy as salvage treatment of small-volume residual ovarian cancer. PATIENTS AND METHODS:We retrospectively examined the surgically defined response rates of patients with ovarian cancer treated at th...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1993.1171

    authors: Markman M,Reichman B,Hakes T,Rubin S,Lewis JL Jr,Jones W,Barakat R,Curtin J,Almadrones L,Hoskins W

    更新日期:1993-07-01 00:00:00

  • Percutaneous nephrostomy catheter use in gynecologic malignancy: M.D. Anderson Hospital experience.

    abstract::The clinical courses of 30 patients with 41 nephrostomy catheters were followed. Duration of drainage ranged from 2 days to 15 months with a mean of 3.7 months. The most common complications were hemorrhage (28%), infection (70%), and blockage of catheter (65%). No deaths occurred as a result of these complications. R...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90303-3

    authors: Dudley BS,Gershenson DM,Kavanagh JJ,Copeland LJ,Carrasco CH,Rutledge FN

    更新日期:1986-07-01 00:00:00